ntrk ESMO Express：从EGFR到NTRK融合，肺癌重要靶点治疗新进展概览

在2020年的ESMO大会壁报摘要内容中，肺癌靶向治疗可谓大放异彩。受全球新冠疫情影响，2020欧洲肿瘤内科学会年会将改为线上虚拟会议形式召开。近年来，肺癌靶向治疗取得诸多进展，并且关注持续热度不减。非小细胞肺癌领域除了常见的人类表皮生长因子受体、间变性淋巴瘤激酶等基因突变，一些少见突变如MET突变/扩增、EGFR 20外显子插入突变、c-ros肉瘤致癌因子-受体酪氨酸激酶融合突变、神经营养因子受体络氨酸激酶融合突变等方面的进展同样备受瞩目。当地时间9月14日，2020的ESMO年会壁报摘要内容公布，肺癌靶向治疗可谓大放异彩。 1295P：FLAURA中国研究OS数据公布，获益趋势与全球数据保持一致Ⅲ期FLAURA研究头对头比较了第三代EGFR-TKI奥希替尼与第一代药物吉非替尼/厄洛替尼一线治疗EGFR突变晚期NSCLC的疗效和安全性。在整体人群中，奥希替尼组的中位总生存期达到38.6个月，较对照组延长了6.8个月，具有显著的统计学差异。FLAURA中国研究先前的数据显示，相比对照组，奥希替尼同样能够显著延长主要终点PFS。本次ESMO大会公布了FLAURA中国研究的次要终点OS结果：奥希替尼组和对照组的中位随访时间分别为31.0个月和24.9个月，OS成熟度分别为63%和68%。奥希替尼组和对照组的中位OS分别为33.1个月和25.7个月，延长了7.4个月，HR=0.85，疾病死亡风险降低15%，具有OS获益趋势，有显著的临床价值。值得注意的是，在FLAURA中国队列中，奥希替尼和标准EGFR-TKI治疗的中位OS数据均略短于FLAURA全球数据，可能是由于中国队列中纳入了更多一般健康状态评分更差的患者。

李宝生教授

博士、博士生导师

山东省泰山学者岗位特聘专家

中华医学会放射肿瘤学分会常务委员

中国抗癌协会放射肿瘤学分会副主任委员

中国医师协会放射肿瘤学分会主任委员

山东省医师协会放射肿瘤学分会主任委员

山东省医学会放射肿瘤学分会前任主委

参考文献

1. Cheng Y, et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated advanced NSCLC: FLAURA China study overall survival . ESMO 2020, abstract 1295P.

2. Planchard D, et al. Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation -positive advanced NSCLC: Safety run-in results from the FLAURA2 study. ESMO 2020，abstract 1401P.

3. G.D. Marijn Veerman, et al. Correlating osimertinib and erlotinib pharmacokinetics with efficacy and toxicity in EGFR-mutated NSCLC patients . ESMO 2020，abstract 1343P.

4. Tao Tian, et al. EGFR T790M ctDNA abundance and TP53 co-mutation by next generation sequencing predicted clinical outcomes of osimertinib in non-small cell lung cancer patients from a real-world study. ESMO 2020，abstract 1369P.

5. D. Ross Camidge, et al. Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort. ESMO 2020，abstract 1414TiP.

6. Egbert F. Smit, et al. INSIGHT 2: Tepotinib + osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification . ESMO 2020，abstract 1415TiP.

7. Jian Zeng, et al. Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA EGFR-mutant non-small cell lung cancer: Results from the ADJUVANT study. ESMO 2020，abstract 1238P.

8. K. Nakagawa, et al. RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type. ESMO 2020，abstract 1294P.

9. K. Nakagawa, et al. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR mutated metastatic non-small cell lung cancer : Exposure-response relationship. ESMO 2020，abstract 1298P.

10. Diansheng Zhong, et al. Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study. ESMO 2020，abstract 1342P.

11. Cho BCC, et al. Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients with ALK+ non-small cell lung cancer in the ASCEND-8 trial. ESMO 2020, abstract 1348P.

12. Krebs MG, et al. Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis. ESMO 2020, abstract 1284P.

13. Drilon A, et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion lung cancer. ESMO 2020, abstract 1289P.